Wednesday, July 8, 2026
🇺🇸 FDA

Drug profile · INN

cabazitaxel

CABAZITAXEL ACCORD

cabazitaxel (CABAZITAXEL ACCORD) is a tubulin inhibitor. Associated with Lacuna Pharma Pty Ltd. Route of administration: injection. Current US regulatory status: approved.

FDA: approved EMA: approved TGA: approved Antineoplastic and immunomodulating agents (L01) L01CD04
US status approved
Patents linked 12
Pipeline programs 9
News articles 0
Drug details — cabazitaxel
US status
approved
Class
Antineoplastic and immunomodulating agents (L01)
Route
INJECTION
Patents
12
Programs
9
Data quality
0.89
← All drugs Manufacturer profile Related patents Pipeline programs Drug news hub Event calendar

Quick answer

cabazitaxel (CABAZITAXEL ACCORD) is a tubulin inhibitor. Associated with Lacuna Pharma Pty Ltd. Route of administration: injection. Current US regulatory status: approved.

Key facts

INN cabazitaxel
Brand CABAZITAXEL ACCORD
Mechanism Tubulin inhibitor
Target Tubulin
Therapeutic class Antineoplastic and immunomodulating agents (L01)
Route INJECTION
Formulation INJECTABLE
ATC code L01CD04
Originator Lacuna Pharma Pty Ltd

Mechanism of action

Tubulin inhibitor

Primary target: Tubulin

Approval history

Authority Status Date
FDA approved —
EMA approved —
TGA approved —

Pipeline programs

Search pipeline Sponsor programs
  1. 20230005 Phase 3 · Amgen · Metastatic castration-resistant prostate cancer (mCRPC)
  2. 20230239 Phase 3 · Amgen · Metastatic castration-resistant prostate cancer (mCRPC)
  3. CABAZITAXEL Phase 3 · Sanofi Pasteur MSD · Prostate Cancer Metastatic
  4. JEVTANA 60 mg concentrate and solvent for solution for infusion. Phase 3 · Ningbo Cancer Hospital · Patients with localized prostate cancer and high-risk featur
  5. Niraparib tosylate monohydrate + abiraterone... for Prostate Cancer Phase 3 · George Institute for · Prostate Cancer
  6. CDZR123A12107 Phase 2 · Novartis India · Metastatic castrate resistant prostate cancer (mCRPC)
  7. DAROTAXEL Phase 2 · Disc Medicine · metastatic castration-resistant prostate cancer
  8. MK-5684-01A Phase 2 · MSD Merck Sharp · Metastatic castration resistant prostate cancer (mCRPC)

Related & competitor drugs

Browse all drugs
  1. abiraterone acetate Antineoplastic and immunomodulating agents (L02)
  2. anagrelide Antineoplastic and immunomodulating agents (L01)
  3. apremilast Antineoplastic and immunomodulating agents (L04)
  4. arsenic trioxide Antineoplastic and immunomodulating agents (L01)
  5. axitinib Antineoplastic and immunomodulating agents (L01)
  6. azacitidine Antineoplastic and immunomodulating agents (L01)

Related patents

Browse patents Lacuna Pharma Pty Ltd patent hub

  1. US 10894087

    Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds

    Expires Mon Jan 14 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. EP 3093014

    CABAZITAXEL UND DESSEN VERWENDUNG ZUR BEHANDLUNG VON KREBS

    Expires Tue Nov 11 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. WO 2015104417

    UTILISATION DU CABAZITAXEL POUR LE TRAITEMENT DE L'ADÉNOCARCINOME GASTRIQUE

    Expires Wed Jul 11 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. WO 2015036507

    UTILISATION DE CABAZITAXEL CHEZ DES PATIENTS CHEZ QUI UN CANCER DU POUMON NON À PETITES CELLULES MÉTASTATIQUE CONTINUE À PROGRESSER APRÈS UN TRAITEMENT À BASE DE DOCÉTAXEL

    Expires Wed Mar 14 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. CA 2903132

    CABAZITAXEL ET SON UTILISATION POUR LE TRAITEMENT DES CANCERS DE LA PROSTATE METASTATIQUES

    Expires Thu Sep 07 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. EP 2678011

    ANTITUMORIGENE KOMBINATON, DIE CABAZITAXEL UND CISPLATIN UMFASST

    Expires Tue Dec 27 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. CA 2864029

    NOUVELLES UTILISATIONS PEDIATRIQUES DU CABAZITAXEL

    Expires Wed Aug 10 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. EP 2620148

    Antitumorkombination mit Cabazitaxel und Cisplatin

    Expires Tue Jul 26 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. WO 2013088335

    FORME CRISTALLINE DE CABAZITAXEL ET PROCÉDÉ POUR PRÉPARER CELLE-CI

    Expires Wed Jun 15 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 2012301425

    NOVEL ANTITUMORAL USE OF CABAZITAXEL

    Expires Wed Nov 24 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. EP 2491925

    Antitumorigene Kombinaton, die Cabazitaxel und Cisplatin umfasst

    Expires Tue Aug 24 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. CA 2708489

    UTILISATION ANTITUMORALE NOUVELLE DU CABAZITAXEL

    Expires Thu Apr 24 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is cabazitaxel?

cabazitaxel (CABAZITAXEL ACCORD) is a tubulin inhibitor. Associated with Lacuna Pharma Pty Ltd. Route of administration: injection. Current US regulatory status: approved.

What is the brand name for cabazitaxel?

CABAZITAXEL ACCORD is a marketed brand name for cabazitaxel. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of cabazitaxel?

cabazitaxel has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.